SCHEMBL2456510

SCHEMBL2456510

O=C(Nc1ccccc1C(=O)Nc1n[nH]c2c1CN(S(=O)(=O)c1cccnc1)CC2)c1ccc[nH]1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 2/20 0.60
MET P08581 4/20 0.46
CHRNB2 P17787 2/20 0.42
CHRNA4 P43681 2/20 0.42
CHRNB4 P30926 1/20 0.42
CHRNA3 P32297 1/20 0.42
PPARG P37231 1/20 0.38
PPARD Q03181 1/20 0.38
POLB P06746 1/20 0.36
NAMPT P43490 1/20 0.36
KDM4E B2RXH2 1/20 0.35
AURKA O14965 1/20 0.35
CCNA2 P20248 1/20 0.35
CDK2 P24941 1/20 0.35
CCNA1 P78396 1/20 0.35
EP300 Q09472 2/20 0.35
CREBBP Q92793 2/20 0.35
HTT P42858 1/20 0.35
F2 P00734 1/20 0.34
F12 P00748 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1891163 0.89 IGF1R (0.57) IGF1RMETCHRNB2CHRNA4CHRNB4
SCHEMBL1890579 0.88 IGF1R (0.62) IGF1RMETCHRNB2CHRNA4CHRNB4
SCHEMBL1889294 0.88 IGF1R (0.62) IGF1RMETCHRNB4CHRNA3PPARG
SCHEMBL1893778 0.87 IGF1R (0.76) IGF1RMETPPARGPPARDPOLB
SCHEMBL1890202 0.87 IGF1R (0.69) IGF1RMETCHRNB2CHRNA4NAMPT
SCHEMBL1893031 0.85 IGF1R (0.72) IGF1RMETPPARGPPARDPOLB
SCHEMBL2678725 0.84 MET (0.50) IGF1RMETCHRNB2CHRNA4CHRNB4
SCHEMBL2678720 0.84 MET (0.50) IGF1RMETCHRNB2CHRNA4CHRNB4
SCHEMBL1373681 0.84 IGF1R (0.55) IGF1RPPARGPPARDAURKACCNA2
SCHEMBL1893061 0.84 IGF1R (0.45) IGF1RMETCHRNB2CHRNA4CHRNB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110230470-A1 SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-09-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230470-A1 SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS MAP3K3, MAP3K1, MAP3K19 IGF1R 760/4885MET 1089/4885CHRNB2 4588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.